180 related articles for article (PubMed ID: 16427438)
21. A phase I trial of perillyl alcohol in patients with advanced solid tumors.
Azzoli CG; Miller VA; Ng KK; Krug LM; Spriggs DR; Tong WP; Riedel ER; Kris MG
Cancer Chemother Pharmacol; 2003 Jun; 51(6):493-8. PubMed ID: 12695855
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
[TBL] [Abstract][Full Text] [Related]
23. [Chemotherapy for malignant gliomas: an update].
Wakabayashi T; Natsume A; Fujii M
Gan To Kagaku Ryoho; 2013 Oct; 40(10):1283-7. PubMed ID: 24105052
[TBL] [Abstract][Full Text] [Related]
24. Perillyl alcohol, a pleiotropic natural compound suitable for brain tumor therapy, targets free radicals.
Gomes AC; Mello AL; Ribeiro MG; Garcia DG; Da Fonseca CO; Salazar MD; Schönthal AH; Quirico-Santos T
Arch Immunol Ther Exp (Warsz); 2017 Aug; 65(4):285-297. PubMed ID: 28314870
[TBL] [Abstract][Full Text] [Related]
25. Intranasal administration of the chemotherapeutic perillyl alcohol results in selective delivery to the cerebrospinal fluid in rats.
Nehra G; Andrews S; Rettig J; Gould MN; Haag JD; Howard SP; Thorne RG
Sci Rep; 2021 Mar; 11(1):6351. PubMed ID: 33737566
[TBL] [Abstract][Full Text] [Related]
26. Circulating Cell-Free DNA as a Prognostic and Molecular Marker for Patients with Brain Tumors under Perillyl Alcohol-Based Therapy.
Faria G; Silva E; Da Fonseca C; Quirico-Santos T
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29848970
[TBL] [Abstract][Full Text] [Related]
27. [Recent advances in chemotherapy for malignant gliomas].
Yoshino A; Katayama Y
No Shinkei Geka; 2008 Feb; 36(2):173-83. PubMed ID: 18265701
[No Abstract] [Full Text] [Related]
28. Temozolomide and treatment of malignant glioma.
Friedman HS; Kerby T; Calvert H
Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
[TBL] [Abstract][Full Text] [Related]
29. Anti-leukemia effect of perillyl alcohol in Bcr/Abl-transformed cells indirectly inhibits signaling through Mek in a Ras- and Raf-independent fashion.
Clark SS; Zhong L; Filiault D; Perman S; Ren Z; Gould M; Yang X
Clin Cancer Res; 2003 Oct; 9(12):4494-504. PubMed ID: 14555523
[TBL] [Abstract][Full Text] [Related]
30. Effects of perillyl alcohol on melanoma in the TPras mouse model.
Lluria-Prevatt M; Morreale J; Gregus J; Alberts DS; Kaper F; Giaccia A; Powell MB
Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):573-9. PubMed ID: 12050099
[TBL] [Abstract][Full Text] [Related]
31. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.
Hudes GR; Szarka CE; Adams A; Ranganathan S; McCauley RA; Weiner LM; Langer CJ; Litwin S; Yeslow G; Halberr T; Qian M; Gallo JM
Clin Cancer Res; 2000 Aug; 6(8):3071-80. PubMed ID: 10955786
[TBL] [Abstract][Full Text] [Related]
32. Approaches toward improving the prognosis of pediatric patients with glioma: pursuing mutant drug targets with emerging small molecules.
Snape TJ; Warr T
Semin Pediatr Neurol; 2015 Mar; 22(1):28-34. PubMed ID: 25976258
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy for malignant gliomas.
Kreisl TN
Semin Radiat Oncol; 2009 Jul; 19(3):150-4. PubMed ID: 19464629
[TBL] [Abstract][Full Text] [Related]
34. Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy.
Chen TC; Fonseca CO; Schönthal AH
Am J Cancer Res; 2015; 5(5):1580-93. PubMed ID: 26175929
[TBL] [Abstract][Full Text] [Related]
35. The effects of tibolone on the human primary glioblastoma multiforme cell culture and the rat C6 glioma model.
Altinoz MA; Albayrak SB; Karasu A; Sabanci PA; Imer M; Bilir A
Neurol Res; 2009 Nov; 31(9):923-7. PubMed ID: 19531283
[TBL] [Abstract][Full Text] [Related]
36. Anti-thrombin as a prognostic biomarker candidate for patients with recurrent glioblastoma multiform under treatment with perillyl alcohol.
Fischer Jde S; Carvalho PC; Neves-Ferreira AG; da Fonseca CO; Perales J; Carvalho Mda G; Domont GB
J Exp Ther Oncol; 2008; 7(4):285-90. PubMed ID: 19227008
[TBL] [Abstract][Full Text] [Related]
37. Conventional chemotherapy and perspectives for molecular-based oncological treatment in pediatric hemispheric low-grade gliomas.
Fernández MB; Alonso VP
Childs Nerv Syst; 2016 Oct; 32(10):1939-45. PubMed ID: 27659836
[TBL] [Abstract][Full Text] [Related]
38. [Animal models of human glioma: the progress of application and investigation].
Zhu HF; Zhang YX; Zhao XD
Dongwuxue Yanjiu; 2012 Jun; 33(3):337-42. PubMed ID: 22653863
[TBL] [Abstract][Full Text] [Related]
39. Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives.
Liu J; Yang F; Hu J; Zhang X
CNS Neurosci Ther; 2024 May; 30(5):e14715. PubMed ID: 38708806
[TBL] [Abstract][Full Text] [Related]
40. Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas.
Iwadate Y; Fujimoto S; Tagawa M; Namba H; Sueyoshi K; Hirose M; Sakiyama S
Int J Cancer; 1996 Jun; 69(3):236-40. PubMed ID: 8682593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
